Can TB-500 cause side effects in research models?
The published preclinical literature on TB-500 and full-length thymosin β4 reports a favourable safety profile in animal models, with no prominent adverse-effect signals at typical research-protocol dose tiers. Human safety data is limited and primarily from venous-ulcer and corneal-research contexts.
What the research literature says
The TB-500 (and parent thymosin β4) preclinical safety framework spans cardiac repair (PMID 15565145, PMID 22236126), dermal healing (PMID 27450738), corneal repair (PMID 11950239, PMID 27450739), and limb-ischemia angiogenesis (PMID 32945357). Across these studies the adverse-effect signals are not prominent in the published findings; the literature is dominated by the efficacy framework rather than safety concerns.
Human-safety data is limited to small clinical trials. The Guarnera venous-ulcer trial documented safety and tolerability data in a European prospective randomised study (PMID 17495250). The Sosne corneal-research framework covers human-context safety considerations (PMID 27450739, PMID 41235866). The published preclinical safety profile is favourable but the human-cohort framework is narrower than for the long-established pharmaceutical-class compounds.
Researchers framing safety assessments should be explicit about the preclinical-vs-clinical distinction in the underlying data. Animal-model safety findings do not automatically extrapolate to humans; the absence of large clinical trials means rare-event risk categories remain less-characterised than for FDA-approved compounds.
Why this matters in research context
The safety question matters in peptide-research contexts because protocol design depends on the underlying safety framework. TB-500’s favourable preclinical safety profile supports the multi-week protocol designs typical across the published research literature; researchers should anchor safety expectations to the published preclinical data while applying appropriate caveats about extrapolation beyond the studied dose ranges and protocol durations.
Related compounds
- TB-500 10mg — the compound covered by this answer
Related research questions
References
- Guarnera G et al. Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. Ann N Y Acad Sci 2007;1112:407-412. [PMID 17495250]
- Bock-Marquette I et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004;432(7016):466-472. [PMID 15565145]
- Kleinman HK et al. Thymosin β4 Promotes Dermal Healing. Vitam Horm 2016;102:251-275. [PMID 27450738]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. TB-500 is sold strictly as a research-grade reagent for laboratory and bench research applications.